Accord Healthcare has struck a licensing deal with Myovant Sciences that will give Accord exclusive European commercialization rights for the Orgovyx (relugolix) treatment for advanced hormone-sensitive prostate cancer.
Accord Adds To Oncology Offering With Orgovyx
Deal For Prostate Cancer Drug Follows Camcevi Leuprolide Launch In US
Accord Healthcare has struck a European licensing deal with Myovant Sciences for its Orgovyx (relugolix) treatment for advanced hormone-sensitive prostate cancer. The move comes shortly after sister company Accord Biopharma launched the Camcevi (leuprolide) prostate cancer treatment in the US.
